Yili Chuanning BiotechnologyLtd Balance Sheet Health
Financial Health criteria checks 6/6
Yili Chuanning BiotechnologyLtd has a total shareholder equity of CN¥7.6B and total debt of CN¥1.4B, which brings its debt-to-equity ratio to 18.6%. Its total assets and total liabilities are CN¥10.6B and CN¥3.0B respectively. Yili Chuanning BiotechnologyLtd's EBIT is CN¥1.7B making its interest coverage ratio 33.7. It has cash and short-term investments of CN¥624.8M.
Key information
18.6%
Debt to equity ratio
CN¥1.41b
Debt
| Interest coverage ratio | 33.7x |
| Cash | CN¥624.79m |
| Equity | CN¥7.59b |
| Total liabilities | CN¥2.96b |
| Total assets | CN¥10.55b |
Recent financial health updates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11
We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Recent updates
These 4 Measures Indicate That Yili Chuanning BiotechnologyLtd (SZSE:301301) Is Using Debt Safely
Oct 11If EPS Growth Is Important To You, Yili Chuanning BiotechnologyLtd (SZSE:301301) Presents An Opportunity
Jul 23We Think Yili Chuanning BiotechnologyLtd (SZSE:301301) Can Manage Its Debt With Ease
May 31Yili Chuanning BiotechnologyLtd (SZSE:301301) Could Easily Take On More Debt
Feb 26Financial Position Analysis
Short Term Liabilities: 301301's short term assets (CN¥4.1B) exceed its short term liabilities (CN¥2.0B).
Long Term Liabilities: 301301's short term assets (CN¥4.1B) exceed its long term liabilities (CN¥965.2M).
Debt to Equity History and Analysis
Debt Level: 301301's net debt to equity ratio (10.4%) is considered satisfactory.
Reducing Debt: 301301's debt to equity ratio has reduced from 106.6% to 18.6% over the past 5 years.
Debt Coverage: 301301's debt is well covered by operating cash flow (75.4%).
Interest Coverage: 301301's interest payments on its debt are well covered by EBIT (33.7x coverage).